We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Treatment of Androgenetic Alopecia in Males

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00947505
Recruitment Status : Completed
First Posted : July 28, 2009
Results First Posted : July 30, 2012
Last Update Posted : July 30, 2012
Information provided by (Responsible Party):
Lexington International, LLC

Brief Summary:
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 7 Beam model in promoting hair growth in males diagnosed with androgenetic alopecia when treatment is applied as directed.

Condition or disease Intervention/treatment Phase
Androgenetic Alopecia Hair Loss Male Pattern Baldness Device: HairMax LaserComb 2009, 7 Beam Device: HairMax LaserComb Not Applicable

Detailed Description:

This is randomized, double-blind, control device clinical study across 2 sites, evaluating changes in terminal hair-count in the evaluation zone having evidence of androgenetic alopecia (miniaturized hair).

The trial will involve 45 male subjects who have been diagnosed with androgenetic alopecia, who are between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of Norwood-Hamilton IIa to V, have active hair loss within the last 12 months.

Subjects will use the device on three nonconcurring days a week as directed per device for 26 weeks treatment duration.

Initial efficacy endpoint for each subject will be assessed at visit 4 (week 16).

Safety analysis will be assessed based on the reports of adverse events during study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Control Device Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 7 Beam Model: For the Treatment of Androgenetic Alopecia in Males
Study Start Date : August 2009
Actual Primary Completion Date : August 2010
Actual Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: HairMax LaserComb 2009, 7 Beam
Lower level laser phototherapy medical device with 7 laser beams
Device: HairMax LaserComb 2009, 7 Beam
Device application 3 times week (non-consecutive days), for 26 weeks
Other Name: HairMax LaserComb

Active Comparator: Control Device
Identical to the Active device, but with 7 LED's instead of lasers
Device: HairMax LaserComb
Device application 3 times week (non-consecutive days), for 26 weeks
Other Name: Control device

Primary Outcome Measures :
  1. Changes in Terminal Hair Count at 16 and 26 Weeks Over Baseline [ Time Frame: 16 and 26 weeks ]
    Results of terminal hair count will be compared to baseline for each user between active and control devicea at 26 weeks with an interim evaluation at week 16. Terminal hair count, which is non-vellus/non-miniaturized hair counts, will be assessed in the target region

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Diagnosis of androgenetic alopecia
  • Fitzpatrick Skin Types I-IV
  • Norwood-Hamilton IIa to V
  • Active hair loss within last 12 months

Exclusion Criteria:

  • Photosensitivity to laser light
  • Malignancy in the target area

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00947505

Layout table for location information
United States, Florida
Abe Marcadis, M.D.
Palm Beach, Florida, United States, 33409
United States, Texas
Michael Jarratt, MD
Austin, Texas, United States, 78759
Sponsors and Collaborators
Lexington International, LLC
Layout table for investigator information
Principal Investigator: Michael Jarratt, M.D. DermaResearch, Inc.
Principal Investigator: Abe Marcadis, M.D. Palm Beach Research Center
Layout table for additonal information
Responsible Party: Lexington International, LLC
ClinicalTrials.gov Identifier: NCT00947505    
Other Study ID Numbers: 7 2009-M-01
First Posted: July 28, 2009    Key Record Dates
Results First Posted: July 30, 2012
Last Update Posted: July 30, 2012
Last Verified: June 2012
Keywords provided by Lexington International, LLC:
Androgenetic alopecia
Hair loss
Male Pattern baldness
Additional relevant MeSH terms:
Layout table for MeSH terms
Alopecia Areata
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical